Core Viewpoint - Polyrizon Ltd. has signed a non-binding Letter of Intent with a biotech company focused on psychedelic-derived therapeutics to develop a novel intranasal formulation for psychedelic-based treatment applications [1][2]. Group 1: Collaboration Details - The agreement aims to leverage Polyrizon's proprietary platform to optimize the delivery of innovative psychedelic treatments, emphasizing the potential of intranasal drug delivery in enhancing bioavailability, efficacy, and patient accessibility [2][4]. - Polyrizon will lead the formulation's development using its mucoadhesive drug delivery technology, while the psychedelic company will fund the research and development process, including feasibility studies [4]. Group 2: Technology and Innovation - Polyrizon specializes in developing innovative medical device hydrogels delivered as nasal sprays, which create a barrier in the nasal cavity to protect against viruses and allergens [5]. - The company's proprietary Capture and Contain (C&C) hydrogel technology aims to improve bioadhesion and prolonged retention at the nasal deposition site for drug delivery [5]. Group 3: Future Prospects - If the collaboration is successful, it could lead to further clinical development and commercialization, with plans to negotiate a definitive agreement outlining intellectual property ownership, commercialization rights, and financial terms [4]. - Polyrizon is expected to receive royalty payments for any future commercialization of the product by the psychedelic company [4].
Polyrizon Signs Non– Binding LOI to Expand its Innovative Intranasal Drug Delivery Platform for Psychedelic-Based Treatments